← Leaderboards
Donna Keith
Privo Technologies, Llc
$4,266,547
Attributed
$8,533,093
Total exposure
3
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2018–24$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$8,533,093 · 3
By mechanism
R44$8,533,093 · 3
Top collaborators
- Manijeh N Goldberg11 shared
Most similar at Privo Technologies, Llc
Same institution · by research overlap
- Manijeh N Goldberg$11,254,955
- Jesse Hall$523,684
- Marcus Webb$1,664,854
- Kuanju Chen$110,338
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsEnsureMalignant Mouth NeoplasmCisplatinNanoengineeringPharmaceutical PreparationsHourTumorFoundationsFundingToxic EffectIntravenousMalignant NeoplasmsSurvival RateChemotherapyRecurrenceCostIncidenceExcisionAmericanOperative Surgical ProceduresChemotherapeutic AgentNanoparticleNeoplasm Metastasis
Grant awards (11)
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$1,012,303
R44 · FY2024 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$987,292
R44 · FY2023 · CA
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$984,664
R44 · FY2023 · DE
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$779,005
R44 · FY2022 · DE
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings$401,107
R44 · FY2022 · CA
Commercialization of Safe and Effective Locoregional Head and Neck Cancer Therapy$1,183,038
R44 · FY2021 · DE
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,000,447
R44 · FY2020 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$1,083,847
R44 · FY2019 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$98,000
R44 · FY2019 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$4,318
R44 · FY2019 · CA
Supportive Clinical Trial Tasks for Nanotechnology-Based Treatment of Oral Cancer$999,072
R44 · FY2018 · CA